Table 25 Anti-tumor activities of synthesized derivatives in different cell lines
From: Biological potential of thiazolidinedione derivatives of synthetic origin
Compounds | Diseases | Cancer cell line | Log GI50 (μM) | Log10 TGI (μM) |
|---|---|---|---|---|
76 | Leukemia | K-562 | > − 0.4 | > − 4.0 |
Breast cancer | MCF-7 | − 4.53 | > 4.0 | |
Hepatoma | HEPG-2 | > − 4.0 | > 4.0 | |
NSC lung cancer | HOP-62 | − 6.72 | − 4.54 | |
Prostate cancer | PC-3 | − 4.53 | > − 4.0 | |
Oral cancer | GURAV | > − 4.0 | > − 4.0 | |
Nasopharyngeal cancer | KB | > − 4.0 | > − 4.0 | |
77 | Leukemia | K-562 | > − 4.0 | > − 4.0 |
Breast cancer | MCF-7 | > − 4.0 | > − 4.0 | |
Hepatoma | HEPG-2 | > − 4.0 | > − 4.0 | |
NSC lung cancer | HOP-62 | − 6.73 | > − 4.0 | |
Prostate cancer | PC-3 | > − 4.0 | > − 4.0 | |
Oral cancer | GURAV | > − 4.0 | > − 4.0 | |
Nasopharyngeal cancer | KB | > − 4.0 | > − 4.0 | |
78 | Leukemia | K-562 | − 6.72 | > − 4.0 |
Breast cancer | MCF-7 | − 6.71 | − 4.52 | |
Hepatoma | HEPG-2 | > − 4.0 | > − 4.0 | |
NSC lung cancer | HOP-62 | > − 4.0 | > − 4.0 | |
Prostate cancer | PC-3 | − 5.60 | > − 4.0 | |
Oral cancer | GURAV | − 6.73 | − 4.52 | |
Nasopharyngeal cancer | KB | − 5.65 | > − 4.0 | |
79 | Leukemia | K-52 | > − 4.0 | > − 4.0 |
Breast cancer | MCF-7-5 | − 4.60 | > − 4.0 | |
Hepatoma | HEPG-2 | > − 4.0 | > − 4.0 | |
NSC lung cancer | HOP-62 | − 6.77 | > − 4.0 | |
Prostate cancer | PC-3 | − 4.55 | − 4.54 | |
Oral cancer | GURAV | > − 4.0 | > − 4.0 | |
Nasopharyngeal cancer | KB | > − 4.0 | > − 4.0 | |
Doxorubicin | Leukemia | K-562 | − 5.59 | > − 4.0 |
Breast cancer | MCF-7 | − 6.88 | − 5.68 | |
Hepatoma | HEPG-2 | > − 7.0 | − 6.87 | |
NSC lung cancer | HOP-62 | − 6.91 | − 4.45 | |
Prostate cancer | PC-3 | − 6.96 | − 5.68 | |
Oral cancer | GURAV | − 6.97 | − 6.80 | |
Nasopharyngeal cancer | KB | > − 7.0 | − 6.85 |